This suggests PPAR is a promising therapeutic target for CRC tumor cells, particularly relevant given that, despite substantial preclinical evidence, PPAR inhibitors have not yet seen widespread effective use in CRC patient treatment. Here, PPARA is linked to colorectal carcinoma.